BIO vs MTD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

BIO

59.1
AI Score
VS
BIO Wins

MTD

37.8
AI Score

Investment Advisor Scores

BIO

Nov 10, 2026
59score
Recommendation
HOLD

MTD

Nov 10, 2026
38score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric BIO MTD Winner
Forward P/E 41.6667 32.8947 MTD
PEG Ratio 1.1905 3.1978 BIO
Revenue Growth 0.5% 6.3% MTD
Earnings Growth 18.7% 16.3% BIO
Tradestie Score 59.1/100 37.8/100 BIO
Profit Margin 39.5% 22.2% BIO
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation HOLD AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

BIO 1M: +6.1% · 3M: +6.7% MTD 1M: +12.1% · 3M: +21.7%

Current Technical Phase

BIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 58

RSI (14): 58.2 · Price: $386.48

MTD

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (7.4% over 20 days), RSI 68

RSI (14): 67.7 · Price: $1751.38

Fundamentals Snapshot

Metric BIO MTD
Market Cap — —
Forward P/E 39.0 32.9
Trailing P/E 10.3 38.3
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.5% 0.6%
Operating Margin 0.1% 0.3%
EPS 37.64 46.07
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.